



A statement from Biogen on LEQEMBI™ pricing

January 6, 2023

Biogen would like to commend our collaboration partner, Eisai, on today's U.S. Food and Drug Administration approval of LEQEMBI™ via the Accelerated Approval pathway. Additional details can be found in a [news release](#) announcing the approval. An additional news release from Eisai on patient safety is [available on Eisai's website](#).

A separate news release from Eisai on LEQEMBI pricing is also [available via their website](#). Eisai is solely responsible for setting LEQEMBI's price.